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Introduction: This study analyzed the risk of clinical trial failure 
during non–small-cell lung cancer (NSCLC) drug development 
between 1998 and January 2012. We also looked for factors that 
impacted clinical trial risk in NSCLC.
Methods: NSCLC drug development was investigated using trial 
disclosures from http://www.clinicaltrials.gov and other publically 
available resources. Compounds were excluded from the analysis 
if they had begun phase I clinical testing before 1998, did not use 
 treatment-relevant endpoints, or if they did not have a completed 
phase I trial in NSCLC. Analysis was conducted in regard to treat-
ment indication, compound classification, and mechanism of action.
Results: Six hundred seventy-six clinical trials that included 199 
unique compounds met our inclusion criteria. The likelihood, or 
cumulative clinical trial success rate, that a new drug would pass 
all phases of clinical testing and be approved was found to be 11%, 
which is less than industry aggregate rates. Over half of the biomark-
ers used in NSCLC have not yet been approved by the Food and 
Drug Administration in any indication. Biomarker targeted therapies 
(62%) and receptor targeted therapies (31%) were found to have the 
highest success rates. The risk-adjusted cost for NSCLC clinical drug 
development was calculated to be U.S. $1.89 billion. 
Conclusion: Biomarker use alone in this indication resulted in a 
sixfold increase in clinical trial success whereas receptor targeted 
therapies did so by almost threefold. Physicians who enroll patients 
in NSCLC trials should prioritize their participation in clinical trial 
programs that use biomarkers and receptor targeted therapies.
Key Words: Non–small-cell lung cancer, Risk analysis, Drug 
 development, Clinical trials.
(J Thorac Oncol. 2014;9: 163–169)
The treatment and prevention of lung cancer is a large focus of the medical community because of its substan-
tial burden of disease. Lung cancer was the leading cause of 
 cancer-related deaths worldwide with an estimated 1.37 mil-
lion deaths caused in 2008 alone,1 and was also found to be 
the third leading cause of death in high-income countries, 
exceeded only by ischemic heart disease and cerebrovascu-
lar disease.1 This large clinical focus on lung cancer and the 
oncology sector has led to the pursuit of new and innovative 
treatment therapies by the biopharmaceutical industry, which 
in turn has led to a tremendous increase in the funding of 
oncology drug development over the last decade with a partic-
ularly large interest in non–small-cell lung cancer (NSCLC).2,3
This study built upon the emerging risk analysis research 
in other disease indications.4–9 NSCLC drug development was 
analyzed in comparison with the cumulative industry clinical 
trial data from the study by DiMasi et al.15 This is the first 
study to quantify the specific risk of drug failure during clini-
cal testing for NSCLC.
Our study focused on advanced or metastatic 
(stage IIIb–IV) NSCLC. There has been a large amount of 
recent pharmaceutical innovation in this therapeutic area, with 
five therapies approved for this disease indication over the last 
decade, which include the biologic bevacizumab10 and the small 
molecules gefitinib,11 erlotinib,12 pemetrexed,13 and crizotinib.14
MATERIALS AND METHODS
Similar study methodology has been described and used 
in the risk analysis of other disease indications.4–9 Note that 
under the most recent tumor, node, metastasis classification 
stage IIIb lung cancer with pleural effusion is now classified 
as stage IV. We used the 2005 version as valid during the time-
frame of the study.
NSCLC Study Eligibility and Study  
Patient Population
Phase I, II, and III clinical trials for the treatment of 
locally advanced or metastatic (stage IIIb–IV) NSCLC that 
took place between 1 January 1998 and 1 January 2012 were 
analyzed. Compounds must have completed a phase I trial 
during this time period to be included, and any compound 
that began clinical development before this time period was 
excluded from the analysis. Chemosensitizers and drugs that 
were used to treat secondary complications of NSCLC were 
also excluded from the study. All industry rates for  comparison 
were taken from the study by DiMasi et al.15
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Databases and Online Tools
The primary source of clinical trial data that was used in 
this analysis was the public clinical trial repository that can be 
accessed through the Web site http://clinicaltrials.gov/. This 
database was supplemented with other publically available 
resources to confirm and find additional clinical trial data. The 
following search terms were used: non small cell lung cancer 
+ phase 1, non small cell lung cancer + phase 2, non small cell 
lung cancer + phase 3, non small cell lung cancer + approval, 
non small cell lung cancer + news. Additional searches were 
done using specific parameters to obtain information about a 
particular study compound or about a specific clinical trial.
Classification of Clinical Trial Success
A compound that had completed a phase I clinical trial 
was classified as successful if there was an ongoing, completed, 
or currently recruiting phase II clinical trial found. A com-
pound that had completed a phase II clinical trial was similarly 
classified as successful if there was an ongoing, completed, 
or currently recruiting phase III found. A compound that had 
completed a phase III clinical trial was classified as successful 
if there was an official Food and Drug Administration (FDA)–
approved indication in our study population. In the rare case that 
a compound had obtained an FDA approval without the comple-
tion of a phase III trial, we considered the phase III portion of 
drug development to be successful. In addition, a phase I/II trial 
was classified as a phase II trial and a phase II/III trial was clas-
sified as a phase III trial for analysis purposes. A compound was 
judged to have unsuccessfully completed a clinical trial if there 
were safety issues that led to developmental termination, if a 
compound failed to reach their primary endpoints, or if a com-
pound did not progress to the next phase of development within 
2 years. Follow-up was completed until January 1, 2012.
Treatment Indication Classification
A separate analysis was performed for compounds that 
can be classified under four different treatment indications 
in locally advanced or metastatic (stage IIIb–IV) NSCLC: 
 first-line therapy, treatment failure therapy, maintenance ther-
apy, and biomarker targeted therapy.16 Compounds were classi-
fied based on patient enrolment criteria as: first-line therapy if 
patients who had not taken any prior chemotherapy treatment 
for locally advanced or metastatic disease;16 treatment failure 
therapy if patients had failed previous chemotherapy treatment 
for locally advanced or metastatic disease;16 maintenance ther-
apy if the patient’s disease had not progressed after four cycles 
of platinum-based first-line chemotherapy and whose disease 
was currently being treated to maintain and not decrease tumor 
size16; and last, as biomarker targeted therapy in patients who 
exhibited a specific biomarker in their NSCLC. Compounds 
could be included in multiple analyzes if their clinical trials 
occurred in more than one of these treatment indications.
Mechanism of Action and Molecule  
Classification
Compounds were also classified by mechanism of action, 
and the majority of compounds could be classified under five 
different mechanisms. The five mechanisms of action that were 
analyzed were as follows: angiogenesis inhibitors, enzyme 
inhibitors, receptor targeted therapies, immunotherapy, and 
cell-cycle inhibitors. A compound could be classified under 
more than one mechanism if it had multiple modes of thera-
peutic action. Compounds that targeted ligands were included 
in the receptor targeted therapy classification. The mecha-
nism of action classifications were obtained from the U.S. 
Pharmacopeia model guidelines17 and the National Cancer 
Institute.18 Compounds were further classified and analyzed as 
small-molecule drugs or biologics. Biologics were classified as 
any antibody-derived entity, fusion protein, or vaccine.
Calculation of Clinical Trial and 
Clinical Drug Development Costs
Data from an expert source in the pharmaceutical indus-
try with extensive oncology experience, were used to calcu-
late the costs of clinical drug development for stage IIIb- IV 
NSCLC drug development. To calculate the risk-adjusted 
clinical drug development cost, a 9% yearly discounted rate 
was used to estimate the costs in present-day currency.19 From 
an analysis of our clinical trial data, a clinical trial length of 
2.5 years was used for phase I trials, a length of 4 years was 
used for phase II trials, and a 5-year length was used for phase 
III trials. All costs are in U.S dollars (USD).
RESULTS
After using the search process described in Methods 
section, 2407 clinical trial listings were found, yielding 676 
clinical trials, which included 199 unique compounds that 
fulfilled our inclusion criteria. In addition, an additional 42 
compounds were found to be currently undergoing phase I 
clinical trials in our patient population. During the analyzed 
timeframe, five medications were approved with an indica-
tion for the treatment of stage IIIb–IV NSCLC, which include 
the biologic bevacizumab and the small molecules gefitinib, 
erlotinib, pemetrexed, and crizotinib. Crizotinib was unique 
among the compounds as it is only indicated as therapy for 
NSCLC that is positive for the anaplastic lymphoma kinase 
(ALK) biomarker.20 Among the five drugs that were approved 
for the treatment of stage IIIb–IV NSCLC, each drug was 
found to have a set of treatment indications for different 
patient populations. Compounds that were tested in these spe-
cific patient populations were separated and analyzed in com-
parison with the industry-wide expectations for clinical trial 
success rates (Figs .1 and 2).
The clinical trial success rates for stage IIIb–IV 
NSCLC therapies were classified by indication in comparison 
with aggregate industry clinical trial success rate estimates 
(Fig, 1). From these data, it can be seen that the cumula-
tive pass rate for stage IIIb–IV NSCLC therapies overall is 
only 11% in comparison with the 16.5% industry estimation. 
Phase I was the only development phase where success rates 
in NSCLC compounds overall were higher than the aggregate 
industry expectations (95% versus 64%). The phase II over-
all NSCLC success rates were similar to the industry rates 
(42% versus 39%), but the phase III success rates in overall 
NSCLC compounds were much lower than the industry aver-
age (28% versus 66%).
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The clinical trial success rates for stage IIIb–IV 
NSCLC compounds tested in a biomarker targeted indi-
cation were compared with NSCLC compounds that did 
not involve biomarkers in their inclusion criteria (Fig. 2). 
This figure also contains a parallel analysis that includes 
 small-molecule compounds only. The clinical trial success 
rates for stage IIIb–IV NSCLC biomarker targeted therapy 
displayed much higher clinical trial success rates at all 
phases in comparison with the industry aggregate levels,15 
and had higher success rates in phase II and phase III trials 
when compared with NSCLC compounds that did not use 
biomarkers (67% versus 40% and 100% versus 29%, respec-
tively). Note that crizotinib, a biomarker targeted therapy, 
had all three phases of its drug development deemed a suc-
cess despite receiving FDA approval without the completion 
of a phase III trial. The cumulative pass rate of biomarker 
targeted therapy for stage IIIb–IV NSCLC was found to be 
62%, which was much higher than the industry aggregate 
value of 19%. There were a variety of biomarkers that were 
used in the biomarker treatment indications, with the most 
FIGURE 1.  Clinical trial  success 
rates for stage IIIb–IV NSCLC 
 drug-development compounds being 
tested in various treatment indications 
are displayed along with industry-wide 
clinical trial success rate expectations. 
Transition probability refers to the 
probability of a compound successfully 
transitioning from phase I to phase II, 
phase II to phase III, or phase III to Food 
and Drug Administration approval. The 
number above each bar in a clinical 
trial phase represents the total number 
of compounds that completed that 
clinical trial phase and does not include 
compounds in current active testing in 
that phase. Cumulative pass rates rep-
resent the product of transition prob-
abilities across all three clinical phases 
and are the values shown above each 
bar in this section. NSCLC, non–small-
cell lung cancer.
FIGURE 2.  Clinical trial success rates for stage IIIb–IV NSCLC biomarker targeted and nonbiomarker targeted therapy are 
displayed along with industry-wide clinical trial success rate expectations. The figure displays parallel analyses for success rates 
of small-molecule compounds and success rates across all compound types. Transition probability refers to the probability of a 
compound successfully transitioning from phase I to phase II, phase II to phase III, or phase III to Food and Drug Administration 
approval. The number above each bar in a clinical trial phase represents the total number of compounds that completed that 
clinical trial phase and does not include compounds in current active testing in that phase. Cumulative pass rates represent 
the product of transition probabilities across all three clinical phases and are the values shown above each bar in this section. 
NSCLC, non–small-cell lung cancer.
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common one being the EGFR mutation biomarker and the 
only FDA-approved biomarker in this disease being the 
ALK biomarker. Of the 11 biomarkers used in NSCLC, six 
have not yet been approved by the FDA in any indication, 
and only two of the 27 biomarker compounds used the 
 NSCLC-approved ALK biomarker (Table 1).
The use of small-molecule and biologic drugs were 
compared with industry values reported for each category as a 
whole15 (Fig. 3). From this analysis the cumulative pass rate for 
biologics in stage IIIb–IV NSCLC was 17%, which was much 
lower than the industry aggregate value of 32%, and the small-
molecule cumulative pass rate was found to be 10% in NSCLC, 
which was slightly less than the industry aggregate value of 13%.
Mechanisms of action were also analyzed with respect 
to their impact on clinical trial risk (Fig. 4).The angiogenesis 
inhibitors (bevacizumab), enzyme inhibitors (pemetrexed), 
and receptor targeted therapies (bevacizumab, crizotinib, gefi-
tinib, erlotinib) contained an approved compound. Receptor 
targeted therapies had a cumulative pass rate of 31%, which 
was well above the industry average of 19%. In contrast, the 
worst performing mechanism of action was immunotherapy, 
with a cumulative success rate of 6%.
The risk-adjusted and -unadjusted total costs at each 
phase of stage IIIb–IV NSCLC drug development were calcu-
lated for different compound indications (Fig. 5). The approx-
imate clinical trial costs for each phase were obtained from 
an expert source in the pharmaceutical industry with exten-
sive experience in the oncology drug development sector. The 
clinical trial cost estimates were 50 million USD for a phase 
I trial, 100 million USD for a phase II trial, and 200 million 
USD for a phase III trial. This expert source also estimated 
that an average stage IIIb–IV NSCLC compound underwent 
five phase I trials, seven phase II trials, and four phase III tri-
als. The unadjusted clinical trial costs did not factor in any 
risk for trial failure, whereas adjusted clinical trial costs took 
clinical trial success rates into account. The total risk-adjusted 
clinical trial testing cost in present day-dollars for stage 
FIGURE 3.  Clinical trial success rates for stage IIIb–IV NSCLC drug development are displayed along with industry-wide clinical 
trial success rate expectations for both small-molecule and biologic drugs. Transition probability refers to the probability of a 
compound successfully transitioning from phase I to phase II, phase II to phase III, or phase III to Food and Drug Administration 
approval. The number above each bar in a clinical trial phase represents the total number of compounds that completed that 
clinical trial phase and does not include compounds in current active testing in that phase. Cumulative pass rates represent 
the product of transition probabilities across all three clinical phases and are the values shown above each bar in this section. 
NSCLC, non–small-cell lung cancer.
TABLE 1.  Breakdown of Biomarker Targeted Stage IIIb–IV 
Non–Small-Cell Lung Cancer Therapies
Biomarker
Number of  
Compounds
Highest Phase 
of Drug 
Development  
in NSCLC
FDA  
Approval in  
Any Indication
Anaplastic lymphoma 
kinase 
2 Approved Approved
Epidermal growth factor 
receptor 
14 In phase III Approved
KRAS 5 In phase II Approved
Estrogen receptor 1 In phase II Approved
BRAF 2 In phase II Approved
Human leukocyte antigen 1 Failed phase II Not approved
NRAS 1 In phase II Not approved
MEK1 1 In phase II Not approved
Wild-type retinoblastoma 
protein
1 In phase II Not approved
Lewis-Y antigen 2 Failed phase II Not approved
Interleukin-4 receptor 1 Failed phase I Not approved
Statistics for biomarker targeted stage IIIb–IV NSCLC therapies are shown. 
Compounds that were being tested for more than one biomarker in the same clinical 
study were counted under each of the biomarkers tested.
NSCLC, non–small-cell lung cancer; FDA, Food and Drug Administration; KRAS, 
Kirsten rat sarcoma viral oncogene homolog; BRAF, v-raf murine sarcoma viral 
oncogene homolog B; NRAS, neuroblastoma RAS; MEK1, mitogen-activated protein/
extracellular signal-regulated kinase 1.
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IIIb–IV NSCLC was calculated to be 1.89 billion USD for a 
single approved drug.
DISCUSSION
The aim of this study was to quantify the risk of clini-
cal trial failure in NSCLC drug development and identify fac-
tors that impact that risk. The analysis consisted of NSCLC 
clinical trials conducted from 1998 to January 2012. The 
probability of progressing through the phases of drug devel-
opment for compounds with different treatment indications 
and mechanistic classifications was determined using these 
data. Advanced or metastatic (stage IIIb–IV) NSCLC had 
an 11% cumulative success rate, which was much less than 
the industry cumulative success rate of 16.5%. Biomarker 
targeted therapies had a 62% cumulative success rate, much 
higher than the 11% observed in drugs without a biomarker 
targeted indication. This is a sixfold increase in clinical trial 
success for NSCLC. Further, drugs that operated through tar-
geting receptors provided the largest cumulative success rate 
of 31%. These results suggest that there are treatment modali-
ties and drug design strategies that can serve to decrease 
 drug-development risk to promote the production of innova-
tive NSCLC compounds. Regardless of indication, there was 
an overall trend indicating that success rates became worse 
with each new phase of testing, suggesting that earlier phases 
of testing currently did little to help ensure later-stage success. 
FIGURE 4.  Clinical trial success 
rates for stage IIIb–IV non– small-
cell lung cancer drug-development 
compounds classified by mechanism 
of action are displayed along with 
industry-wide clinical trial success 
rate expectations. Transition prob-
ability refers to the probability of a 
compound successfully transitioning 
from phase I to phase II, phase II to 
phase III, or phase III to Food and 
Drug Administration approval. The 
number above each bar in a clinical 
trial phase represents the total num-
ber of compounds that completed 
that clinical trial phase and does not 
include compounds in current active 
testing in that phase. Cumulative 
pass rates represent the product 
of transition probabilities across all 
three clinical phases and are the 
values shown above each bar in this 
section.
FIGURE 5.  Clinical trial costs for 
each phase are displayed for each 
treatment indication. The number 
above each bar represents the cost 
in millions of USD for each treatment 
indication clinical trial phase. The 
total cost of clinical drug develop-
ment was obtained by adding the 
costs of all three clinical trial phases 
together. NSCLC, non–small-cell lung 
cancer; USD, U.S. dollars.
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The risk-adjusted costs for NSCLC clinical drug development 
was calculated to be 1.89 billion USD, but dropped substan-
tially to 1.40 billion USD if conducted with a biomarker. It is 
possible that savings would be even more significant if cou-
pling drug and biomarker development decreased the num-
ber of trials needed to be done before marketing approval. 
As an example, the FDA approved crizotinib based on two 
 single-arm phase I/II studies that included only 255 patients. 
From these findings, it may be possible to design clinical trials 
in NSCLC that have much improved success rates.
Remarkably, biomarker trials had success rates six 
times higher than studies in NSCLC that did not use a bio-
marker. Such results support the recent trend in oncology and 
general drug development toward targeted and personalized 
medications.21,22 The human epidermal growth factor recep-
tor 2 (HER2) biomarker in advanced metastatic breast cancer 
patients was found to reduce clinical trial risk by as much as 
50%, but it was unclear from this study whether the findings 
were merely specific to the biomarker itself.5 The results of 
this study give us reason to believe that risk reduction may be 
a property of biomarker use in general, at least in oncology. 
The recently expedited approval of crizotinib as a treatment 
for patients with the ALK-positive biomarker is a prospective 
example of this trend and shows the regulatory approval and 
support for this type of therapy. The forthcoming appeal of 
biomarker therapy is further underscored by the fact that in 
this data set of compounds that used a biomarker, where, of 27 
biomarker drugs, 25 of the compounds were using 10 differ-
ent biomarkers that have not yet been approved by the FDA in 
this indication. The EGFR mutation biomarker was the most 
often used biomarker in our inclusion criteria, but emerging 
biomarkers like KRAS, BRAF, and novel immunological bio-
markers are beginning to be seen in early-stage trials.
On the basis of these data, physicians should also give 
priority to enrolling their patients in clinical trials involving 
biologics rather than small molecules in NSCLC. When the 
NSCLC compounds were analyzed, it was found that biolog-
ics had a larger cumulative success rate of 17% when com-
pared with the small-molecule success rate of 10%. This is 
despite the fact that four of the five approved drugs in this 
indication were small molecules. The data in Figure 2 show 
that the lack of success of small molecules stems from the 
compounds that were developed without a biomarker, which 
seems to suggest that developing small molecules without 
concurrent biomarker development is not a prudent clinical 
trial strategy in this disease indication.
However, previous studies have found superiority of 
small molecules in breast cancer5 and lymphoma,6 so it seems 
that the disease indication is an important factor in this analy-
sis. The 17% cumulative success rate of NSCLC biologics was 
much lower than the 32% cumulative success rate15 of the aver-
age industry biologic, which suggests that in this indication, 
biologics may be less effective when compared with industry 
rates. Our analysis also suggested that the older mechanism 
of action strategies like cell-cycle inhibition for lung cancer 
and oncology may no longer be the most suitable methodolo-
gies, and physicians participating in clinical trials should give 
priority to studies involving targeted mechanisms of action.
Last, our calculation of risk-adjusted  drug-development 
costs for stage IIIb–IV NSCLC compounds determined the 
cost of clinical drug development for NSCLC to be 1.89 bil-
lion USD. Our cost for stage IIIb–IV NSCLC clinical drug 
development is remarkably similar to the preapproval capital-
ized cost of 1.9 billion USD that was predicted by DiMasi 
et al.23 for a similar time period. Consistent with a similar find-
ing for HER2 in advanced metastatic breast cancers,5 the use 
of a biomarker in NSCLC reduced costs substantially by 26% 
to 1.4 billion USD. The drug-development savings estimated 
in this analysis are likely a conservative figure, as concurrent 
biomarker and drug development can lead to a further reduc-
tion in the quantity of clinical trials needed for each molecule. 
Using our clinical trial cost estimations and clinical trial data, 
we estimated the cost of crizotinib approval to be somewhere 
between 500 and 600 million USD, which is less than a third 
of our cost determination for NSCLC compounds overall. This 
estimation illustrates the tremendous cost-reduction potential 
for biomarker targeted NSCLC strategies.
Our study has several limitations, most of which have 
been described in other research of similar methodology.4–9 
As the sample size of compounds can sometimes grow small 
when doing research on specific disease indications and com-
pound classifications, we see our data as an illustration of pos-
sible trends and future investigations rather than a definitive 
study. Also, combined trials were classified in this analysis 
as a trial of the latter phase for simplicity, which could have 
led to an overestimation of clinical trial success in the early 
phases, as the earlier trial was assumed to be completed if 
there was a combined clinical trial.
CONCLUSION
The cumulative success rate of compounds entering 
NSCLC development is only 11%, which is lower than the rate 
in industry expectations. Biomarker targeted therapies resulted 
in a sixfold increase in clinical trial success, whereas recep-
tor targeted therapies increased success almost threefold. Our 
analysis suggests that biomarker targeted treatment indications 
and compounds that have a receptor targeted mechanism of 
action offer the best chance of clinical success in this indication 
and should be the focus of future clinical trial development.
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